Sign In
Buy XGN
$4.54
-0.280 (-5.81%)
At Close: Jun 03, 2026
Exagen Inc. to Announce Fourth Quarter and Full-Year 2024 Financial Results on March 11, 2025
04:05pm, Tuesday, 25'th Feb 2025
CARLSBAD, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, will release financial results for the quarter and year ended December 31, 2024
Strength Seen in Exagen (XGN): Can Its 29.4% Jump Turn into More Strength?
07:41am, Wednesday, 05'th Feb 2025
Exagen (XGN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in th
Exagen Inc. to Participate in Upcoming Investor Conferences
04:05pm, Tuesday, 04'th Feb 2025
CARLSBAD, Calif., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, today announced that management will participate in the following upcoming in
New biomarkers on track for commercial launch in January 2025 Preliminary financial results indicate record full-year revenue and AVISE CTD trailing twelve-month ASP, with improvements to adjusted EBI
Exagen Inc. Achieves Key Milestone with 1,000,000th Patient Tested by AVISE® CTD
09:00am, Thursday, 12'th Dec 2024
The milestone demonstrates AVISE CTD's value and adoption within the rheumatologic community, clearly demonstrating superior laboratory testing for improved patient care The milestone demonstrates AVI
Exagen Inc. Completes Validation and Regulatory Submission for New Lupus and Rheumatoid Arthritis Biomarkers on the AVISE® CTD Platform
04:30pm, Thursday, 14'th Nov 2024
Significant enhancements will equip clinicians with even more diagnostic clarity in the treatment of patients with autoimmune disease Significant enhancements will equip clinicians with even more diag
Exagen, Inc. (XGN) Q3 2024 Earnings Call Transcript
01:09pm, Tuesday, 12'th Nov 2024
Exagen, Inc. (NASDAQ:XGN ) Q3 2024 Earnings Conference Call November 12, 2024 8:30 AM ET Company Participants Ryan Douglas – IR John Aballi - President & CEO Jeffrey Black - CFO Conference Call Part
Exagen Inc. (XGN) Reports Q3 Loss, Misses Revenue Estimates
10:25am, Tuesday, 12'th Nov 2024
Exagen Inc. (XGN) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.30. This compares to loss of $0.31 per share a year ago.
Exagen Announces Acceptance of Five Abstracts at 2024 American College of Rheumatology Convergence
04:05pm, Monday, 21'st Oct 2024
CARLSBAD, Calif., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, announced today the acceptance of five abstracts at the 2024 American College
Exagen Inc. to Participate in the 2024 Cantor Global Healthcare Conference
04:05pm, Wednesday, 04'th Sep 2024
CARLSBAD, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the 2024 Cantor Global Healthc
Bears are Losing Control Over Exagen (XGN), Here's Why It's a 'Buy' Now
10:55am, Thursday, 29'th Aug 2024
After losing some value lately, a hammer chart pattern has been formed for Exagen (XGN), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions
Exagen (XGN) Shows Fast-paced Momentum But Is Still a Bargain Stock
09:50am, Monday, 26'th Aug 2024
Exagen (XGN) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading
Exagen Inc. (XGN) Soars to 52-Week High, Time to Cash Out?
10:15am, Friday, 09'th Aug 2024
Exagen (XGN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Fast-paced Momentum Stock Exagen (XGN) Is Still Trading at a Bargain
09:50am, Thursday, 08'th Aug 2024
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Exagen (XGN) could be a great choice. It is one of the several stocks that passed th
Exagen Inc. (XGN) Reports Q2 Loss, Tops Revenue Estimates
10:10am, Monday, 05'th Aug 2024
Exagen Inc. (XGN) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.36. This compares to loss of $0.28 per share a year ago.
